Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
about
Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infectionGut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunityPurinergic Receptors: Key Mediators of HIV-1 Infection and InflammationPro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic ReviewTryptophan Catabolism in Chronic Viral Infections: Handling Uninvited GuestsInfluence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusImpact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageThe role of statins in the setting of HIV infectionA Review of Management of Inflammation in the HIV PopulationEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialFrailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs.A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers.Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected womenRuxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.Modulation of Tryptophan/Serotonin Pathway by Probiotic Supplementation in Human Immunodeficiency Virus-Positive Patients: Preliminary Results of a New Study Approach.Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individualsChanges in metabolic syndrome status after initiation of antiretroviral therapyThe effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfectionRifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial.Soluble CD14 is a nonspecific marker of monocyte activation.CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients.Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.Enhancement of HIV-1 infection and intestinal CD4+ T cell depletion ex vivo by gut microbes altered during chronic HIV-1 infection.Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.Microbiome alterations in HIV infection a review.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation.Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study.Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study.Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected PatientsAssociation between Immune Markers and Surrogate Markers of Cardiovascular Disease in HIV Positive Patients: A Systematic Review.Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction.Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyThe therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study.
P2860
Q26748743-2F919729-3145-4849-9F81-89D3874CBBE3Q26773267-6017CC54-C3BB-4EB5-BC64-5F0D24BA7C28Q26774666-8B3B2315-097E-4F32-A711-BA98C5286CC0Q26774828-2125E9C3-0AAF-4EF2-9FD6-D4053A957828Q26797214-D9BD9100-50B9-4001-8A62-85CCC6A96EBAQ26851535-696EBF4D-289E-4BCE-A107-61118BCCF26EQ27014077-45C56A4B-8372-4026-9F48-83ABCCEA8955Q27027724-0A105C40-74DC-4FD6-960B-485566DADF01Q28078962-2168FB68-55EB-4280-95D7-FE866B052F9AQ28552729-187B97E7-D3A4-4B62-BA16-9A5DA252E2CDQ30248351-8F94F63D-756A-45D8-B31A-67291CE6A17FQ30365593-4A00CDB4-7C8F-440A-BE29-1E984BBF5968Q33167632-008193D2-F470-430A-8218-801B6D1226FEQ33555718-B09F29A9-8B4B-4149-A2B8-D84D74635F61Q33622771-2D239C2A-3B5F-4E09-8904-AA1B7B32B5C9Q33629231-0F7075C9-8602-4284-B880-33681364160FQ33758418-76B6F476-1759-49F7-8DB9-9B1DEEDD20A9Q34612385-FC303F69-8AC4-4F75-A25D-195AAEF289BDQ34674774-4BE0163D-93B7-49DD-9D97-4101F48D31F5Q35072020-DA616192-CFFB-469D-919A-E6BD5D68DD77Q35102590-2C086FB0-5BB8-4F40-B2D1-9CE93993FA81Q35629714-97CFDB28-FE47-444F-9477-ADB3F5A8E8BEQ35676127-FB3F9FAB-7F67-42B2-9E68-9D5527EDADDDQ35801549-4494F492-1880-4D30-BB7F-08EC6541B14CQ35860942-98966563-24FF-4203-BD9B-BA4DF3AAC559Q35892944-143DF5E6-64AA-41A2-82BA-BD00939EF961Q35904816-DA7B4D71-74A9-4C6A-8AC2-BE01C3C83519Q35946623-503937B5-A8D1-41A9-85E0-8C2C94AC6B90Q35974422-6272D9A2-0CCC-4AA9-8429-2CB0AAFC206FQ36001196-DA2FC159-FAE8-469A-A6E3-1100A74B4A07Q36009321-03E2450E-8955-4E4F-9604-9ADD3D1C5AD4Q36078749-4E43B957-8477-4845-BBE8-7D6DBCDCA01CQ36120745-1B17C3E3-9F23-45C7-9A06-8544B491FCFBQ36132003-3B57CBD1-E5B1-4C0C-9B37-B7FD5F65AE99Q36144465-38668E71-1D73-49E8-A90D-1BD4665880C8Q36219873-40C1368A-0A26-4535-A45D-382D2D783BFAQ36249027-E6694587-8E8E-4578-87DD-48825C348CECQ36291721-6314C66E-0CE9-4F47-B845-A3D6E2D43970Q36298753-F84C06BC-6724-467A-A79D-FAC791929767Q36322493-956EB721-5867-4E17-AEF2-006E226D9B3D
P2860
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@ast
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@en
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@nl
type
label
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@ast
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@en
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@nl
prefLabel
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@ast
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@en
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@nl
P2093
P2860
P356
P1476
Soluble markers of inflammatio ...... sive antiretroviral treatment.
@en
P2093
Alan L Landay
Allan R Tenorio
Arjun Seth
Cara C Wilson
Jill Plants
Michael M Lederman
Peter W Hunt
Ronald J Bosch
Supriya Krishnan
P2860
P304
P356
10.1093/INFDIS/JIU254
P407
P577
2014-05-01T00:00:00Z